Abstract
Allergic rhinitis (AR) is caused by an immediate type hypersensitivity reaction in sensitized subjects after exposure to airborn allergens. The interaction of the allergen with a specific IgE antibody attached to the nasal mast cells leads to the local release of vasoactive and inflammatory mediators such as histamine, leukotriene C4 and prostaglandin D2. These mediators cause the nasal allergic symptoms complex of rhinorrhea, nasal obstruction, nasal itching and sneezing, which improve spontaneously or with treatment. Cromolyn sodium and nedocromil sodium are often termed ‘antiallergic drugs’, which are defined here as drugs capable of inhibiting both the early-phase response to challenge and chronic allergic inflammation. They act at the cell membrane levels. Intranasal and ocular formulations of cromones, such as cromoglycate, are available without medical prescription in many countries. Sodium cromoglycate or nedocromil have a good safety profile. They reduce the symptoms of AR, and should be used profilactically, but limited efficacy and the need for frequent dosing are disadvantages.
Keywords: Allergic rhinitis, cromones, cromolyn sodium, nedocromil
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title: Mast Cell Stabilizers in the Treatment of Allergic Rhinitis
Volume: 7 Issue: 1
Author(s): Ilknur Haberal Can and Ethem Erdal Samim
Affiliation:
Keywords: Allergic rhinitis, cromones, cromolyn sodium, nedocromil
Abstract: Allergic rhinitis (AR) is caused by an immediate type hypersensitivity reaction in sensitized subjects after exposure to airborn allergens. The interaction of the allergen with a specific IgE antibody attached to the nasal mast cells leads to the local release of vasoactive and inflammatory mediators such as histamine, leukotriene C4 and prostaglandin D2. These mediators cause the nasal allergic symptoms complex of rhinorrhea, nasal obstruction, nasal itching and sneezing, which improve spontaneously or with treatment. Cromolyn sodium and nedocromil sodium are often termed ‘antiallergic drugs’, which are defined here as drugs capable of inhibiting both the early-phase response to challenge and chronic allergic inflammation. They act at the cell membrane levels. Intranasal and ocular formulations of cromones, such as cromoglycate, are available without medical prescription in many countries. Sodium cromoglycate or nedocromil have a good safety profile. They reduce the symptoms of AR, and should be used profilactically, but limited efficacy and the need for frequent dosing are disadvantages.
Export Options
About this article
Cite this article as:
Can Haberal Ilknur and Samim Erdal Ethem, Mast Cell Stabilizers in the Treatment of Allergic Rhinitis, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2008; 7 (1) . https://dx.doi.org/10.2174/187152308783769177
DOI https://dx.doi.org/10.2174/187152308783769177 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Fasting-Evoked En Route Hypoglycemia in Diabetes (FEEHD): From Guidelines to Clinical Practice
Current Diabetes Reviews Drug-Related Cardiotoxicity for the Treatment of Haematological Malignancies in Elderly
Current Pharmaceutical Design Societal and Cultural Attitudes to Gout: An Important Consideration in the Successful Management of Gout among Maori in Aotearoa New Zealand
Current Rheumatology Reviews Alveolar Capillary Dysplasia: A Lethal Developmental Lung Malformation
Current Respiratory Medicine Reviews Liver Fibrosis and Therapeutic Strategies: The Goal for Improving Metabolism
Current Drug Targets Potential Role of Polyphenols in the Prevention of Cardiovascular Diseases: Molecular Bases
Current Medicinal Chemistry Herbal Medicine for Slowing Aging and Cardiovascular Risk: Mechanisms and Safety
Current Vascular Pharmacology Adipokines: Therapeutic Targets for Metabolic Syndrome
Current Drug Targets Molecular Targeting Agents in Renal Cell Carcinoma: Present Strategies and Future Perspectives
Current Pharmaceutical Design Nutraceutical Targeting of Placental Synthesis of Soluble Fms-Like Tyrosine Kinase- 1 (sFlt-1) as Strategy for Preventing and Controlling Pre-eclampsia
Current Pharmaceutical Design Cholinesterase Inhibitors Modulate Autonomic Function in Patients with Alzheimer´s Disease and Mixed Dementia
Current Alzheimer Research MCM-41-SO3H as an Advanced Nanocatalyst for the Solvent-Free Synthesis of N-aryl-2-amino-1,6-naphthyridine Derivatives
Current Nanoscience Antidiabetic Oils
Current Diabetes Reviews BELFAST Centenarians: A Case of Optimal Cardiovascular Risk?
Current Pharmaceutical Design Conference Report (11th International Conference on Neuroprotective Agents, Wendake, Quebec City, Quebec, Canada, Sept 30-Oct 3, 2012)
CNS & Neurological Disorders - Drug Targets Renal Denervation Therapy: Can it Contribute to Better Blood Pressure Control in Hypertension?
Current Vascular Pharmacology Melatonin: Pharmacology, Functions and Therapeutic Benefits
Current Neuropharmacology Effects of Exercise Training on Delaying Disease Progression in Patients with Chronic Kidney Disease: a Review of the Literature
Reviews on Recent Clinical Trials Effects of the Antidiabetic Drugs on the Age-Related Atrophy and Sarcopenia Associated with Diabetes Type II.
Current Diabetes Reviews Uric Acid Metabolism in Pre-hypertension and the Metabolic Syndrome
Current Vascular Pharmacology